Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

Weiden PJ, Kozma C, Grogg A, Locklear J.

Psychiatr Serv. 2004 Aug;55(8):886-91.

PMID:
15292538
2.

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV.

Am J Psychiatry. 2004 Apr;161(4):692-9.

PMID:
15056516
3.

A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia.

Law MR, Soumerai SB, Ross-Degnan D, Adams AS.

J Clin Psychiatry. 2008 Jan;69(1):47-53.

PMID:
18312037
4.

Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics.

Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Dirani R, Menzin J.

Psychiatr Serv. 2010 Dec;61(12):1239-47. doi: 10.1176/ps.2010.61.12.1239.

PMID:
21123409
5.

Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.

Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR.

Psychiatr Serv. 2003 May;54(5):719-23.

PMID:
12719504
6.

Outpatient antipsychotic treatment and inpatient costs of schizophrenia.

Marcus SC, Olfson M.

Schizophr Bull. 2008 Jan;34(1):173-80. Epub 2007 Jun 19.

7.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
10.

Treatment adherence and insight in schizophrenia.

Bitter I, Fehér L, Tényi T, Czobor P.

Psychiatr Hung. 2015;30(1):18-26.

PMID:
25867885
11.

Risk factors for early readmission to acute care for persons with schizophrenia taking antipsychotic medications.

Boaz TL, Becker MA, Andel R, Van Dorn RA, Choi J, Sikirica M.

Psychiatr Serv. 2013 Dec 1;64(12):1225-9. doi: 10.1176/appi.ps.003382012.

PMID:
23945797
12.

Performance of compliance and persistence measures in predicting clinical and economic outcomes using administrative data from German sickness funds.

Frey S, Stargardt T.

Pharmacotherapy. 2012 Oct;32(10):880-9. doi: 10.1002/j.1875-9114.2012.01120.

PMID:
23033227
13.
14.

Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.

Seabury SA, Goldman DP, Kalsekar I, Sheehan JJ, Laubmeier K, Lakdawalla DN.

Am J Manag Care. 2014 Feb 1;20(2):e52-60.

15.
16.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
17.

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.

Svarstad BL, Shireman TI, Sweeney JK.

Psychiatr Serv. 2001 Jun;52(6):805-11.

PMID:
11376229
18.

Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program.

Ahn J, McCombs JS, Jung C, Croudace TJ, McDonnell D, Ascher-Svanum H, Edgell ET, Shi L.

Value Health. 2008 Jan-Feb;11(1):48-56. doi: 10.1111/j.1524-4733.2007.00214.x.

19.

Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.

Lang K, Federico V, Muser E, Menzin J, Menzin J.

J Med Econ. 2013 Aug;16(8):997-1006. doi: 10.3111/13696998.2013.816310. Epub 2013 Jun 28.

PMID:
23777223

Supplemental Content

Support Center